Fusion Antibodies News

Meet Fusion Antibodies at BIO-Europe 2017

Fusion Antibodies will be attending Bio-Europe 2017 Fusion Antibodies are pleased to announce that Chris Moriarty and Hayley Close from the Fusion Team will be attending Bio-Europe 2017, being held on 6-8th November in Berlin.  Bio-Europe…

Fusion’s Jody Haddow meets Genome BC’s CEO Alan Winter

Fusion Antibodies North American Business Development Agent, Dr Jody Haddow pictured alongside Dr Alan Winter. The recently retired CEO of Genome BC, Dr Alan Winter recently received a lifetime achievement award for his services at the…

The Strategy for UK life sciences: The result So Far:

The life science sector is a key sector and jewel in the crown for the UK economy. The sector contributes a massive annual turnover of £50 Billion, comprises of over 5,000 companies and employs an estimated 175,000 people. The life science…

Fusion Antibodies attending Biojapan 2016

The Fusion Antibodies Team will be attending BioJapan 2016 held in Pacifico Yokohama, Japan this October. BioJapan is Asia’s Leading Bio, Pharma R&D Event (Exhibition, Partnering, Conference) specialised in Biotechnology, Drug…

Alliance between Fusion Antibodies and Nb Health Laboratory

Fusion Antibodies, a UK-based contract research organisation and NB Health Laboratory (NBHL), a Japan-based biotechnology company specialising in GPCR-targeting drug discovery, are entering an alliance for a research and licence agreement in…

Fusion Antibodies and Bizcom Japan continue to strengthen ties.

Fusion Antibodies and BizCom Japan, a privately-held Japan-based trading and consulting company, continue to strengthen ties with Fusion’s Director Paul Kerr attending BioJapan 2016 with BizCom Japan’s Director Hiroyasu Nakatani. BizCom…

Fusion Antibodies sponsoring Antibody Engineering & Therapeutics conference in San Diego

Fusion Antibodies has the privilege of showcasing their expertise and sponsoring the Antibody Engineering & Therapeutics conference in San Diego this December. The Antibody Engineering & Therapeutics conference which began over…

Paul Kerr discusses Antibody Humanization with Pharma TV

Fusion Antibodies managing director Paul Kerr recently met with PharmaTV News' Adrian Dawkes to dissuss our Antibody Humanziation platform. Fusion Antibodies managing director Paul Kerr recently met with PharmaTV News' Adrian Dawkes…

Fusion Antibodies welcomes 20th Human & Hybridoma conference

Fusion Antibodies ltd has the great honour and privilege to welcome the 20th Human Antibodies & Hybridoma conference to our home city of Belfast this November. It continues to be a great time of hope and optimism in the knowledge…

Fusion Antibodies announces Cell Line Development collaboration with Celonic

Fusion Antibodies are happy to announce we have entered into a partnership with Swiss contract manufacturing organisation Celonic AG to collaborate on the development of high yield stable cell lines. The deal will allow clients of Fusion…

Fusion Antibodies seek Business Development Manager

Fusion Antibodies are looking to hire a Business Development Manager to join their team based in Belfast, UK. Are you looking to join an innovative manufacturer of a range of high quality antibodies for drug development and diagnostics?…

Fusion Antibodies announces collaboration with Aerpio Therapeutics for second Antibody Humanization project

Fusion Antibodies are pleased to announce a second collaboration with Aerpio Therapeutics to apply our CDRx Antibody Humanization platform to Aerpio’s Mouse Monoclonal Antibody. Fusion Antibodies Ltd are excited to announce our second…